TELO Telomir Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1971532 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY51.3%
TTM EPS YoY-159.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.3%
ROA-91.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.1%
Debt / equity0.00x
Current ratio19.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $251,887 | $444,674 | $467,797 | $1.30M | $759,525 | $42,839 | $336,996 | $269,083 |
| SG&A expense | $493,309 | $1.32M | $573,539 | $838,472 | $386,951 | $5.03M | $1.85M | $2.64M |
| Operating income | — | — | — | — | — | — | $2.19M | — |
| Interest expense | $1,908 | $3,028 | $1,255 | — | $0 | $1,342 | $46 | -$1 |
| Net income | -$705,225 | -$1.72M | -$990,947 | -$2.06M | -$1.10M | -$5.07M | -$2.18M | -$2.90M |
| EPS (basic) | -0.01 | -0.79 | -0.03 | — | -0.03 | -0.17 | -0.07 | — |
| EPS (diluted) | -0.01 | -0.79 | -0.03 | — | -0.03 | -0.17 | -0.07 | — |
| Weighted avg. shares (diluted) | 68.77M | 60.84M | 34.38M | — | 32.40M | 30.01M | 29.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.52M | $5.17M | $5.56M | $7.29M | $7.33M | $754,323 | $402,999 | $1.27M |
| Current assets | $4.64M | $5.37M | $5.79M | $7.34M | $7.40M | $829,611 | $491,188 | $1.32M |
| Total assets | $4.64M | $5.37M | $5.79M | $7.34M | $7.40M | $829,611 | $491,188 | $1.32M |
| Current liabilities | $236,746 | $332,424 | $827,310 | $1.43M | $422,807 | $348,388 | $652,294 | $680,968 |
| Total liabilities | $236,746 | $332,424 | $827,310 | $1.43M | $422,807 | $348,388 | $652,294 | $680,968 |
| Shareholders' equity | $4.40M | $5.03M | $4.96M | $5.91M | $6.98M | $481,223 | -$161,105 | $643,037 |
| Shares outstanding | 68.77M | 68.77M | 34.38M | 34.38M | 33.83M | 30.51M | 29.76M | 29.76M |
| Cash flow statement | ||||||||
| Operating cash flow | -$586,439 | -$1.01M | -$1.77M | -$1.20M | -$927,264 | -$696,445 | -$863,132 | -$605,808 |
| Financing cash flow | -$68,143 | $622,107 | $47,351 | $1.16M | $7.50M | — | — | $1.04M |
| Stock-based compensation | $65,344 | $198,734 | $39,803 | -$7,949 | $98,142 | $4.66M | $1.38M | $2.06M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.